Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bari – page 29

401 clinical trials in Bari, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bari at a glance
401
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

401 trials in Bari

Open in trial search

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Primary amyloidosis

Not recruiting

Study on Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Systemic AL Amyloidosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer+4

Not recruiting

Study on the Effectiveness and Safety of Osimertinib for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer After Tumor Removal

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer

Not recruiting

Study of MK-2870 and Chemotherapy for Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Long-term Effects of Givinostat for Patients with JAK2V617F Positive Chronic Myeloproliferative Neoplasms

Not recruiting
InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Daratumumab, and Pomalidomide with Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Renal cell carcinoma

Not recruiting

Study of Belzutifan and Palbociclib for Patients with Advanced Renal Cell Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

IgA nephropathy

Not recruiting

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Acute myeloid leukaemia

Not recruiting

Study of venetoclax and azacitidine treatment in adults with NPM1-mutated acute myeloid leukemia who experience molecular relapse or disease progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib with Idelalisib and Rituximab or Bendamustine and Rituximab for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Idelalisib
  • Sponsor:Loxo Oncology Inc.

Diffuse large B-cell lymphoma refractory

Not recruiting

Study on the Safety and Effectiveness of Polatuzumab Vedotin with Rituximab, Gemcitabine, and Oxaliplatin for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Oxaliplatin
  • Sponsor:F. Hoffmann-La Roche AG

Acute lymphocytic leukaemia

Not recruiting

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bari

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Research evaluates new therapeutic approaches and drug combinations.

  • Colorectal Cancer Treatment Studies
  • Lung Cancer Therapies
  • Mesothelioma Management

Advanced clinical trials testing targeted therapies and immunotherapy approaches.

02 Infectious Disease Prevention

Investigations into vaccines and preventive treatments for various infectious conditions, particularly respiratory syncytial virus (RSV) and influenza. Studies include both pediatric and adult populations.

  • Vaccine Development
  • RSV Prevention
  • Influenza Protection

Focus on immunogenicity and safety in different age groups.

03 Hematologic Disorders

Research examining treatments for blood-related conditions, including chronic myeloid leukemia and acute myeloid leukemia. Studies evaluate novel therapeutic approaches and drug combinations.

  • Leukemia Treatments
  • Targeted Therapies
  • Clinical Outcomes

Emphasis on personalized treatment approaches and molecular targeting.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.